Senate Vioxx Hearing To Include Merck’s Gilmartin, FDA’s Crawford
This article was originally published in The Pink Sheet Daily
Executive Summary
A Nov. 18 Senate Finance Committee hearing on the withdrawal of Vioxx will include testimony from Merck CEO Ray Gilmartin
You may also be interested in...
Mifeprex Labeling Change Not A Move Toward Product Withdrawal, FDA Says
Decision to strengthen warnings on the abortifacient was a “routine action” resulting from reports of serious adverse events, CDER Acting Director Galson says. “There was absolutely no political pressure on this,” he says, calling the labeling revision “science-based.”
Mifeprex Labeling Change Not A Move Toward Product Withdrawal, FDA Says
Decision to strengthen warnings on the abortifacient was a “routine action” resulting from reports of serious adverse events, CDER Acting Director Galson says. “There was absolutely no political pressure on this,” he says, calling the labeling revision “science-based.”
Bextra Meta-Analyses Could Be Taken Up At February COX-2 Advisory Cmte.
Drug safety committee member Curt Furberg's meta-analysis suggests increased risk of cardiovascular events for patients with osteoarthritis and rheumatoid arthritis taking Bextra versus placebo while Pfizer points to a meta-analysis of 8,000 patients that did not show an effect. Furberg disinvited by FDA to participate in committee meeting following public comments.